CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to JNJ

Rivaroxaban 2.5 mg

Phase 3
Johnson & Johnson (JNJ)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Acute Coronary Syndrome

View Full Landscape
Drug Information

Target Indication

Acute Coronary Syndrome

Clinical Trial

NCT00809965

Last updated: 12/8/2025

Patent & Exclusivity
ActiveRLD

Latest Patent Expiry

Aug 17, 2034(7y 11m)

Patents Listed

2

Application

NDA 022406
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.